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| INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a severe public health problem and is estimated to cause 686 000 deaths annually worldwide. 1 In China, there are approximately 93 million chronic HBV carriers, 2 accounting for approximately 38% of all HBV-infected patients worldwide. 3 Overall, HBV causes approximately 45% of hepatocellular carcinoma (HCC) cases and 30% of cirrhosis cases. 4 Maintaining viral suppression through antiviral therapy can reduce the occurrence of liver-related complications in these patients. In addition, the accurate assessment of liver fibrosis is crucial to identifying patients who are prone to severe clinical conditions and for making treatment decisions regarding patients with chronic HBV infection. 5 Liver biopsy is currently recognized as the 'gold standard' for estimating liver fibrosis stage; however, this technique is invasive and confers an increased risk of complications. 6 Sampling errors and inter-and intra-observer variability associated with liver biopsy may also make the assessment of liver fibrosis unreliable. 7 Moreover, the dynamic surveillance of liver fibrosis using liver biopsy is limited and noninvasive methods are warranted. FibroScan is a noninvasive method that evaluates liver stiffness and has been reported to accurately reflect liver fibrosis in patients; however, its application in obese patients is limited, and the cost is relatively high. [8] [9] [10] The analysis of blood biomarkers has been recognized as a simple, convenient and inexpensive noninvasive method for the assessment of liver fibrosis. Although several noninvasive models involving blood biomarkers have been developed, these models are far from optimal and have limited clinical value. [11] [12] [13] [14] [15] [16] [17] [18] [19] Among these markers, the FIB-4 index 17 and the aspartate aminotransferaseto-platelet ratio index (APRI) 16, 18, 19 are widely used to assess patients with chronic hepatitis C (CHC), but their value for assessing patients who are chronically infected with HBV remains controversial. 11, 14, 16 Recently, Lemoine et al. identified a novel simple index, the gammaglutamyltransferase-to-platelet ratio (GPR), which exhibited better performance than FIB-4 and APRI in assessing liver fibrosis in chronically HBV-infected West African patients; however, this was not true for French populations. 20 In contrast, Li et al. found that the performance of GPR was inferior to that of APRI for the assessment of liver fibrosis in Chinese populations. 21 Another algorithm, the red cell volume distribution width-to-platelet ratio (RPR), was developed by Chen et al. and was found to be superior to APRI and FIB-4 for predicting significant fibrosis and cirrhosis. 22 The quantitation of hepatitis B surface antigen (HBsAg) and HBV DNA level may be useful for the diagnosis of liver fibrosis in chronically HBV-infected patients. [23] [24] [25] [26] [27] [28] Several clinical studies have compared the utilities of these blood biomarkers for the diagnosis of liver fibrosis, but inconclusive results have been reported. [12] [13] [14] 29 The aims of this study were to systematically compare the diagnostic performance of established blood biomarkers and to establish an improved algorithm for the assessment of liver fibrosis in treatmentnaïve chronically HBV-infected Chinese patients.
| MATERIALS AND METHODS

| Patients
For this study, 1302 consecutive chronically HBV-infected patients, who underwent liver biopsy at Ruijin Hospital (Shanghai, China) from 2008 to 2015, were retrospectively recruited. Chronic HBV infection was defined as having blood that tested positive for HBsAg for at least 6 months. Patients were excluded from this study for the following reasons: excessive alcohol intake (n=46), co-infection with HIV or hepatitis C virus (HCV), a history of other chronic liver diseases (n=67), previous antiviral treatment history (n=214), hepatocellular carcinoma or other types of cancer (n=3) and the lack of sufficient biopsy samples or data pertaining to red cell volume distribution width (RDW), platelet count (PLT), gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (n=356). In total, 616 eligible patients were included in this study and were randomly divided into a training cohort (N=410) and an internal validation cohort (N=216). All subjects provided written informed consent, and the study was performed according to the ethical guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Ruijin Hospital.
| External validation cohort
One external validation set of treatment-naïve HBV-infected patients predictive value and negative predictive value were 63%, 90%, 72% and 80%, respectively. In the internal and external validation cohorts, the performance of the algorithm in assessing liver fibrosis was also superior to that of other biomarkers. 
| Laboratory tests
All blood samples were obtained, and laboratory variables were measured at the time of biopsy based on the manufacturer's instructions. Blood biochemical parameters included ALT, AST and GGT.
Haematological parameters included RDW and PLT. Virological parameters included HBV serological markers and HBV DNA. HBV serological markers were detected using a chemiluminescent microparticle enzyme immunoassay (CMIA, Abbott, Chicago, IL, USA). HBV DNA level was measured using real-time PCR (PJ Co. Ltd., Shenzhen, China) with a lower limit of detection of 500 IU mL −1 .
| Model calculations
GPR, RPR, FIB-4 and APRI were calculated as previously described: www.r-project.org/). A two-sided P value of less than .05 was considered statistically significant.
| RESULTS
| Training cohort
| Baseline characteristics of patients in the training cohort
The flow chart for patient enrolment is shown in Fig. S1 . To assess and validate the diagnostic ability of noninvasive biomarkers, 616 patients from Ruijin Hospital were randomly assigned to a training cohort (N=410) or to an internal validation cohort (N=206). 33 Similar baseline characteristics, hepatic fibrosis distribution and laboratory parameters were identified between the two cohorts ( 
| Correlation between blood biomarkers and the liver fibrosis stage
| Construction of a novel assessment algorithm for significant liver fibrosis
In the training cohort, an optimal GPR cut-off value of 0.1581 generated a sensitivity of 83%, a specificity of 45%, a PPV of 47% and an F I G U R E 1 Box plots of blood gamma-glutamyltranspeptidase-to-platelet ratio (GPR), red cell volume distribution width-to-platelet ratio (RPR), FIB-4 index, aspartate aminotransferase-to-platelet ratio index (APRI) and HBV DNA according to fibrosis stage in the training cohort. The top and bottom of the whiskers represent the minimum and maximum values, respectively. The top and bottom of the boxes represent the first and third quartiles, respectively, and the horizontal lines across the boxes represent the median values. Correlation between the different stages of fibrosis was calculated using the Kruskal-Wallis test or the Mann-Whitney U test .036
*P value for the comparison between the training and internal validation sets. **P value for the comparison between the training and external validation sets. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; RDW, red cell volume distribution width; PLT, platelet count; HBeAg, hepatitis B e antigen; GPR, GGT-to-PLT; RPR, RDW-to-PLT; FIB-4, fibrosis index based on the four factors; APRI, AST-to-PLT ratio index.
NPV of 83% according to Youden's index. The optimal cut-off value of RPR was 0.0804, and the corresponding sensitivity, specificity, PPV and NPV were 63%, 72%, 57% and 77%, respectively. The optimal cut-off value of FIB-4 was 1.1951, and the corresponding sensitivity, specificity, PPV and NPV were 69%, 66%, 54% and 79%, respectively.
The optimal cut-off value of APRI was 0.4135, and the corresponding sensitivity, specificity, PPV and NPV were 84%, 46%, 47% and 83%, respectively. The optimal cut-off value of the HBV DNA level was 7.1, and the corresponding sensitivity, specificity, PPV and NPV were 89%, 54%, 53% and 90%, respectively (Table 2) .
Using the RPART method, we established a novel assessment algorithm with 10-fold cross-validation in the training cohort (Figure 3 ). The combination of HBV DNA level and RPR was found to have the optimal diagnostic value for liver fibrosis in chronically HBV-infected patients.
The corresponding sensitivity, specificity, PPV and NPV of the algorithm were 63%, 90%, 72% and 80%, respectively (Table 2 ). In comparison with previously developed blood biomarkers, the novel algorithm correctly identified 317 cases (77%) of 410 cases, better than the use of any previously developed blood biomarkers alone (P<.001) ( Table 2 ).
| Internal validation cohort
In the internal validation cohort (n=206), 47 (22.80%) cases were F0, 101 (49.00%) cases were F1, 19 (9.20%) were F2, 14 (6.80%) cases F I G U R E 2 Receiver operating characteristics curves of noninvasive blood biomarkers, including gammaglutamyltransferase-to-platelet ratio (GPR), red cell volume distribution width-toplatelet ratio (RPR), FIB-4 index, aspartate aminotransferase-to-platelet ratio index (APRI) and HBV DNA level for diagnosing significant liver fibrosis (F0-1 vs F2-4) in the (A) training cohort and (B)internal validation cohort and (C) external validation cohort. AUC, area under the curve; 95% CI, 95% confidence interval Using the optimal cut-off values derived from the training cohort, the corresponding sensitivity for the novel algorithm was 53%; the specificity was 76%; the PPV was 47%; and the NPV was 87%. The algorithm correctly identified 144 cases (70%) of the total 206 cases in the internal validation cohort, a significantly higher number than those for GPR (P<.0001), RPR (P<.0001), FIB-4 (P=.001), APRI (P<.0001) and HBV DNA (P=.004) ( Table 2 ).
| External validation cohort
The median GGT and PLT were significantly different between the external validation cohort (N=159) and the training cohort. Figure 2C ). However, the AUC for HBV DNA was 0.585 (95% CI = 0.505-0.663), a value that was lower than that for the previously developed blood biomarkers (P<.05). The distribution of the blood biomarkers according to liver fibrosis stage is shown in Fig. S2B .
The performance of the blood biomarkers using the optimal cutoff values derived from the training cohort is shown in Table 2 . Using the optimal cut-off values derived from the training cohort, the corresponding sensitivity for the novel RPR-HBV DNA algorithm was 68%; the specificity was 81%; the PPV was 74%; and the NPV was 76%.
The algorithm correctly identified 119 cases (75%) of the total of 159 cases in the external validation cohort. GPR and HBV DNA correctly identified 96 cases (75%) and 100 cases (63%) out of the total of 159 cases, respectively, significantly lower numbers than those obtained T A B L E 2 Diagnostic performance of the studied blood biomarkers and the established RPR-HBV DNA algorithm for diagnosing significant liver fibrosis in treatment-naïve and chronically hepatitis B virus-infected patients No. incorrect diagnosis (n, %) 168 (41) 128 (31) 136 (31) 164 (40) 137 (33) 93 (23) Internal validation cohort No. biopsy correctly avoided (n, %)
111 (54) 130 (63) 119 (58) 105 (51) 119 (58) 144 (70) No. incorrect diagnosis (n, %) 95 (46) 76 (37) 87 (42) 101 (49) 87 (42) 62 (30) External validation cohort The diagnostic ability of the RPR-HBV DNA algorithm is significantly different from those of GPR and HBV DNA.
using the algorithm (P=.009 for GPR and P=.001 for HBV DNA). RPR,
FIB-4 and APRI correctly identified 109 cases (69%), 107 cases (67%)
and 105 cases (66%) out of the total of 159 cases, respectively; these values were lower than those obtained using the algorithm, but the differences were not significant (P=.099 for RPR, P=.104 for FIB-4 and P=.087 for APRI; Table 2 ).
| DISCUSSION
Early detection of significant fibrosis is essential for reaching antiviral therapy decisions in chronically HBV-infected patients. 4 The present study compared the diagnostic value of previously established blood biomarkers including GPR, RPR, FIB-4 and APRI for assessing liver fibrosis in a large population of Chinese patients with chronic HBV infection and established a novel algorithm for the assessment of liver fibrosis that yielded better performance than previous methods. ; however, these biomarkers exhibit lower sensitivity and specificity in clinical use, and their diagnostic value is limited and controversial for chronically HBV-infected patients. [14] [15] [16] [40] [41] [42] In our study, the performance of FIB-4 was slightly superior to that of APRI in the training cohort, but the diagnostic value of these markers was comparable in the internal and external validation cohorts. The discrepancy may be due to the small sample size of the validation cohort and the different basic characteristics of the included patients.
Lemoine et al. developed a noninvasive biomarker, GPR, for diagnosing liver fibrosis in chronically HBV-infected patients. 20 The authors found that GPR was superior to APRI and FIB-4 in two African cohorts, but the diagnostic performance of these biomarkers were similar in a French cohort. Li et al. found that GPR was inferior to APRI but comparable to FIB-4 in Chinese patients chronically infected with HBV. 21 However, when restricted to patients with high HBV DNA levels and normal or mildly elevated ALT levels, GPR performed better than APRI and FIB-4 in the assessment of liver fibrosis. 43 In the current study, we found that the performance of GPR was comparable to that of APRI and FIB-4 among patients with chronic HBV infection in both the training and validation sets. Previous studies showed that for evaluating significant fibrosis, the AUC of GPR ranges from 0.66 to 0.80. Using the optimal cut-off value, the corresponding sensitivity ranged from 49% to 83%, and the specificity ranged from 43% to 83%. 20, 21, 43 The difference in the diagnostic ability of GPR between these studies may be caused by differences in the basic characteristics and spectrum bias in the fibrosis distribution of these patients. The GPR index was generated based on GGT and PLT. GGT can be affected by biliary tract disease and by some types of drugs, 44, 45 and this had not been evaluated in the reported studies. Thus, the value of GPR for the assessment of liver fibrosis in patients with chronic HBV infection needs to be determined using further studies, and other clinical factors that may affect the GPR level should be identified.
Chen et al. reported the use of another noninvasive biomarker, RPR, to evaluate liver fibrosis in Chinese chronically HBV-infected patients. 22 The authors concluded that RPR is a more powerful 48 HBV DNA levels were lower in chronically HBV-infected and treatment-naïve patients with fibrosis compared to the levels in those without fibrosis and this marker may have diagnostic value for evaluating liver fibrosis in treatment-naïve patients. 23, 27 With the ROC method, we found that HBV DNA levels had comparable diagnostic value for liver fibrosis compared to FIB-4, APRI, RPR and GPR in the training and internal validation cohorts. When using the optimal cut-off, the NPV for HBV DNA level was high (90%, 94% and 72% in the training, internal validation and external validation cohorts, respectively); however, the PPV was low (53%, 39% and 56% in the training, internal validation and external validation cohorts, respectively). Using the RPART method,
we established a novel RPR-HBV DNA algorithm that provided better diagnostic performance for liver fibrosis in the training cohort than any individual blood biomarker. Using the algorithm, 77% of patients were correctly identified. Importantly, the novel algorithm consisted of conventional blood biomarkers and the results of virological testing, which are routinely obtained in the management of chronically HBV-infected patients; no extra tests that would increase the medical burden on the patients are required. However, although the algorithm achieved high specificity and NPV, these came at the cost of sensitivity and PPV. In the external validation cohort, even though no significant difference existed between the results obtained using the algorithm and those obtained using individual biomarkers, the number of patients who were correctly diagnosed using the algorithm was higher than that obtained using individual biomarkers; this result might be due to differences in the basic characteristics of the patients and the small sample size of the external validation cohort. The FibroScan has been used to evaluate liver fibrosis in chronically HBV-infected patients based on a determination of liver stiffness; however, the FibroScan is relatively expensive, and specialized technicians are needed. This test is unavailable in less developed countries and regions. In the current study, we did not compare the performance of the algorithm and FibroScan due to the lack of FibroScan data for the recruited patients. A comparison between the algorithm and FibroScan using well-designed studies is warranted.
Several limitations should be acknowledged. First, this study was retrospective and used data obtained from two clinical centres. The results should be validated in prospective multicentre studies using larger sample sizes. Second, the distribution of fibrosis stage in chronically HBV-infected patients may differ between clinical studies, and the diagnostic performance of conventional blood biomarkers may be influenced by patient characteristics. Third, other clinical confounding factors such as quantitative HBsAg levels and HBV genotype may affect the liver fibrosis caused by HBV, and these factors should be considered in future studies.
In conclusion, we compared the use of conventional blood biomarkers, including GPR, RPR, FIB-4 and APRI, for evaluating liver fibrosis in Chinese patients with chronic HBV infection and established a novel algorithm for the assessment of liver fibrosis. More studies are warranted to confirm the diagnostic value of the algorithm for treatment-naïve chronically HBV-infected patients.
